Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alkixen
- Development stage
- Unknown
- Lead developer
- Everest Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alkixen is a small molecule tyrosine kinase inhibitor (TKI) developed and manufactured by Everest Pharmaceuticals. Its active ingredient is crizotinib, which targets anaplastic lymphoma kinase (ALK) and ROS1. It is primarily indicated for the treatment of ALK-positive anaplastic large cell lymphoma (ALCL) and is also used in the treatment of ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). By inhibiting these kinases, Alkixen disrupts downstream signaling pathways that promote tumor cell growth and survival. It is formulated as a 250 mg capsule for oral administration.
- Brand names
- Alkixen
- Other names
- crizotinib
02
Targets
MST1R (Recepteur d'origine nantais)ALK fusion (Anaplastic lymphoma kinase (ALK) fusion protein)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on Alkixen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alkixen.